E
CALA

Ergoteles’s Calithera Biosciences, Inc CALA Stock Holding History

Ergoteles’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-965
Closed -$13K – 1770
2021
Q4 		$13K Sell
965
-12,775
-93% -$321K ﹤0.01% 1194
2021
Q3 		$599K Sell
13,740
-1,305
-9% -$56.3K 0.02% 517
2021
Q2 		$629K Buy
+15,045
New +$661K 0.01% 691

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Ergoteles's CALA Position: Q1 2022 in Review

Ergoteles sold out of Calithera Biosciences, Inc (CALA) in Q1 2022, closing a stake of 965 shares — an estimated $13K sold.

Ergoteles first reported a position in CALA in Q2 2021 and held it in 3 quarters. The position peaked at $629K in Q2 2021. 54 funds tracked by Wall St. Rank hold CALA as of Q1 2022.

  • Ergoteles reported no remaining Calithera Biosciences, Inc position as of Q1 2022 after selling out during the quarter.
  • Ergoteles sold 965 Calithera Biosciences, Inc shares in Q1 2022, an estimated $13K.
  • Ergoteles first reported a position in Calithera Biosciences, Inc in Q2 2021 and held it in 3 quarters.
  • Ergoteles's Calithera Biosciences, Inc position peaked at $629K in Q2 2021.
  • 54 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.